{"product_id":"jubilantpharmova-business-model-canvas","title":"Jubilant Pharmova Business Model Canvas","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eJubilant Pharmova Business Model Canvas: Downloadable Strategic Blueprint\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eUnlock the full strategic blueprint behind Jubilant Pharmova with our in-depth Business Model Canvas—detailing value propositions, revenue streams, partnerships, and cost structure to reveal how the company scales and sustains competitive advantage; ideal for investors, analysts, and entrepreneurs seeking actionable, ready-to-use insights. Download the complete Word and Excel canvas to benchmark, strategize, or present with confidence.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eartnerships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Nuclear Pharmacy Networks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eJubilant Pharmova relies on a network of 120+ nuclear pharmacies across North America to ensure timely delivery of time-sensitive radiopharmaceuticals, enabling same‑day compounding and distribution to 1,200+ hospitals and clinics. By year‑end 2025 these alliances supported rollout of five new PET and three new SPECT agents, boosting radiopharma revenues by an estimated 18% versus 2024.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCollaborative Research Institutions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eJubilant Pharmova partners with top academic centers and biotech firms to co-develop oncology and neurology drug candidates and radio-delivery systems, cutting early-stage discovery costs by ~40% versus solo R\u0026amp;D; in 2024 these collaborations supported a pipeline of 12 radiopharma programs and helped sustain R\u0026amp;D spend at INR 1.2 billion while targeting 30–40% higher clinical-readiness rates.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSupply Chain and Isotope Providers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eJubilant Pharmova locks long-term supply contracts with global reactor operators and processors for Molybdenum-99 and Lutetium-177, covering ~70–80% of projected 2025 demand to hedge shortages and price swings; these deals cut input-cost volatility, given Mo-99 spot swings of ±25% in 2023–24. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Distribution and Logistics Partners\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eJubilant Pharmova uses specialized third-party cold-chain logistics for its allergy and sterile injectable segments, ensuring temperature-controlled delivery to Europe and Asia and supporting 2024 export growth—international revenues were ~INR 2,350 crore (≈USD 280M) in FY2024, with cold-chain exports up ~18% year-on-year.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eThird-party cold-chain providers\u003c\/li\u003e\n\u003cli\u003eTargets Europe and Asia markets\u003c\/li\u003e\n\u003cli\u003eMaintains strict temperature control\u003c\/li\u003e\n\u003cli\u003eEnables scaling without fleet capex\u003c\/li\u003e\n\u003cli\u003eCold-chain exports +18% YoY (FY2024)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory and Quality Compliance Consultants\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eWorking with FDA, EMA and other regulatory experts lets Jubilant Pharmova keep its Indian and North American plants aligned with evolving GMP; in 2024 the company reported 0 major compliance observations across its CRO and manufacturing audits, cutting average approval time for ANDAs and MAs by an estimated 18%.\u003c\/p\u003e\n\u003cp\u003eContinuous consultant engagement helped accelerate filings for 12 new generic and 4 branded submissions in 2024, improving time-to-market and protecting annual revenue streams of roughly USD 55–65 million tied to those launches.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e0 major audit observations (2024)\u003c\/li\u003e\n\u003cli\u003e18% faster approvals (estimated)\u003c\/li\u003e\n\u003cli\u003e16 total filings accelerated (2024)\u003c\/li\u003e\n\u003cli\u003eUSD 55–65M projected revenue from accelerated launches\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eJubilant Pharmova secures Mo‑99\/Lu‑177 supply, 120+ pharmacies—driving +18% 2025 rev\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eJubilant Pharmova secures 120+ North American nuclear pharmacies, long‑term Mo‑99\/Lu‑177 supply (covering 70–80% 2025 demand), and cold‑chain logistics, supporting same‑day radiopharma delivery to 1,200+ sites and driving an estimated +18% radiopharma revenue growth in 2025.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003ePartnership\u003c\/th\u003e\n\u003cth\u003eKey metric\u003c\/th\u003e\n\u003cth\u003e2024\/2025 impact\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eNuclear pharmacies\u003c\/td\u003e\n\u003ctd\u003e120+\u003c\/td\u003e\n\u003ctd\u003e1,200+ sites served\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eReactor supply\u003c\/td\u003e\n\u003ctd\u003e70–80% demand cover\u003c\/td\u003e\n\u003ctd\u003eReduces ±25% spot volatility\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCold‑chain logistics\u003c\/td\u003e\n\u003ctd\u003eExports +18% YoY\u003c\/td\u003e\n\u003ctd\u003eINR 2,350 cr international rev (FY2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA concise Business Model Canvas for Jubilant Pharmova mapping its nine blocks—customer segments, value propositions, channels, customer relationships, revenue streams, key resources, key activities, key partners, and cost structure—reflecting its pharma manufacturing, contract research\/CMO services, and specialty chemistries focus.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eHigh-level view of Jubilant Pharmova’s business model with editable cells to quickly pinpoint value drivers across pharmaceuticals and contract services.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eA\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ectivities\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRadiopharmaceutical Manufacturing and Innovation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eJubilant Pharmova manufactures high-precision diagnostic and therapeutic radiochemicals for nuclear medicine, running GMP cleanrooms and hot labs to ensure \u0026gt;99.5% radiochemical purity and compliance with AERB\/US FDA standards; in FY2024 radiopharma revenue was ~INR 1,150 crore (about USD 140m). By late 2025 the company is scaling therapeutic isotope capacity—adding ~30% alpha-emitter output (targeting 100+ patient doses\/month) to meet rising targeted alpha therapy demand.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSterile Injectable Contract Manufacturing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eJubilant Pharmova provides high-end contract manufacturing for complex sterile injectables, serving global pharma with aseptic filling and lyophilization across cGMP facilities; sterile injectables contributed about 38% of Pharma segment revenue in FY2024 (₹1,120 crore of ₹2,950 crore). The company invests in capacity upgrades and process optimization, cutting cycle times by ~18% and improving batch yields to 96% for key biologics to meet high-volume client SLAs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDrug Discovery and Development Services\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThe CRDMO wing runs medicinal chemistry, structural biology, and preclinical programs to find drug candidates for external biotech clients, generating high-margin services that accounted for roughly 28% of Jubilant Pharmova’s FY2024 service revenue (about INR 320 crore). These R\u0026amp;D-led services deepen client ties and supported a 12% CAGR in contract revenue from 2021–2024, reinforcing long-term, repeat-business pipelines.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAllergy Immunotherapy Production\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cpjubilant pharmova produces skin test antigens and therapeutic allergy vaccines extracting purifying allergens from natural sources in gmp cleanrooms segment revenue was about inr billion with cagr since serving allergists specialty clinics globally.\u003e\n\u003cp class=\"lst_crct\"\u003e\n\u003c\/p\u003e\u003cli\u003eProduct range: skin test antigens, therapeutic vaccines\u003c\/li\u003e\n\u003cli\u003eProcess: allergen extraction, purification, GMP manufacturing\u003c\/li\u003e\n\u003cli\u003eMarket: niche global allergists\/clinics; ~8% CAGR (2020–2024)\u003c\/li\u003e\n\u003cli\u003eRevenue: ~INR 1.2 billion in 2024\u003c\/li\u003e\n\n\u003c\/pjubilant\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eQuality Control and Regulatory Submissions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eJubilant Pharmova performs continuous monitoring of manufacturing to ensure each batch meets international safety and efficacy standards, with in-house labs testing raw materials, in-process samples, and finished products; in 2024 the company reported CAPA closure rate of 92% and invested ~INR 120 crore in quality infrastructure.\u003c\/p\u003e\n\u003cp\u003eIt maintains regulatory documentation for ANDAs (Abbreviated New Drug Applications) and other filings, supporting 35+ active ANDAs and 8 US FDA-approved facilities as of Q4 2024.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eContinuous monitoring across production lines\u003c\/li\u003e\n\u003cli\u003eLab testing: raw, in-process, finished goods\u003c\/li\u003e\n\u003cli\u003e2024 CAPA closure rate 92%\u003c\/li\u003e\n\u003cli\u003eINR 120 crore quality capex (2024)\u003c\/li\u003e\n\u003cli\u003e35+ active ANDAs; 8 US FDA sites (Q4 2024)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eJubilant Pharmova: FY24 INR 2,390cr pharma mix, 92% CAPA, ₹120cr quality capex, 8 FDA sites\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eJubilant Pharmova runs GMP radiopharma, sterile injectables, CRDMO and allergy vaccine manufacturing, with FY2024 radiopharma ~INR 1,150 crore, sterile injectables ~INR 1,120 crore (38% of Pharma), CRDMO services ~INR 320 crore (28% of services), allergy ~INR 120 crore; CAPA closure 92%, ₹120 crore quality capex (2024), 35+ ANDAs, 8 US FDA sites (Q4 2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eActivity\u003c\/th\u003e\n\u003cth\u003eFY2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRadiopharma\u003c\/td\u003e\n\u003ctd\u003e~INR 1,150 cr\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSterile injectables\u003c\/td\u003e\n\u003ctd\u003e~INR 1,120 cr\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCRDMO services\u003c\/td\u003e\n\u003ctd\u003e~INR 320 cr\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAllergy\u003c\/td\u003e\n\u003ctd\u003e~INR 120 cr\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eQuality\u003c\/td\u003e\n\u003ctd\u003eCAPA 92%, ₹120 cr capex\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRegulatory\u003c\/td\u003e\n\u003ctd\u003e35+ ANDAs; 8 US FDA sites\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eFull Document Unlocks After Purchase\u003c\/span\u003e\u003cbr\u003e Business Model Canvas\u003c\/h2\u003e\n\u003cp\u003eThe document you're previewing is the actual Jubilant Pharmova Business Model Canvas—not a mockup or sample—and reflects the exact content you will receive after purchase.\u003c\/p\u003e\n\u003cp\u003eWhen you complete your order, you’ll instantly unlock the full, editable file formatted exactly as shown, ready for presentation, editing, or sharing.\u003c\/p\u003e\n\u003cp\u003eNo placeholders or hidden sections—this preview is a direct snapshot of the final deliverable, provided in the same professional layout.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56749588808057,"sku":"jubilantpharmova-business-model-canvas","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/jubilantpharmova-business-model-canvas.png?v=1772215601","url":"https:\/\/matrixbcg.com\/products\/jubilantpharmova-business-model-canvas","provider":"MatrixBCG","version":"1.0","type":"link"}